Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,467 public trials 2,848 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, not recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

NCT07150104

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Salvador, Estado de Bahia, Brazil
  • GSK Investigational Site Porto Alegre, Rio Grande do Sul, Brazil
  • GSK Investigational Site Halifax, Nova Scotia, Canada
  • GSK Investigational Site Villejuif, France
View Trial Details
Active, not recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
  • GSK Investigational Site Madison, Wisconsin, United States
View all 19 locations
View Trial Details
Active, not recruiting

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01562405

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Emory University Atlanta, Georgia, United States
  • Massachusetts General Hosptial Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

NCT07217119

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Madison, Wisconsin, United States
  • GSK Investigational Site Fitzroy, Victoria, Australia
  • GSK Investigational Site Melbourne, Victoria, Australia
View Trial Details
Active, not recruiting

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700

Conditions
B-cell Malignancies, Bone Marrow Diseases, Hematologic Diseases, +10 more
Locations
  • Uab Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of Alabama At Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Rochester Phoenix, Arizona, United States
  • University of Arizona Cancer Center-Out Pt. Tucson, Arizona, United States
View all 105 locations
View Trial Details
Active, not recruiting

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

NCT04090736

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +4 more
Locations
  • Complejo Hospitalario Universitario de Santiago Santiago de Compostela, A Coruña, Spain
  • Hospital Txagorritxu Vitoria-Gasteiz, Alava, Spain
  • ICO Badalona- Hospital Universitari Germans Trias i Pujol Badalona, Barcelona, Spain
  • ICO Hospitalet- Hospital Duran i Reynals Hospitalet Del Llobregat, Barcelona, Spain
View all 62 locations
View Trial Details

Related conditions